Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A China Interventional Phase II, Single Arm, Multicenter Study Evaluating the Effectiveness and Safety of Darolutamide + ADT as Neo-Adjuvant Treatment in Treatment-naïve Patients Who Have Planned for Radical Prostatectomy (RP) With High Risk Localized Prostate Cancer

NCT07450599 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT07450599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07450599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A China Interventional Phase II, Single Arm, Multicenter Study Evaluating the Effectiveness and Safety of Darolutamide + ADT as Neo-Adjuvant Treatment in Treatment-naïve Patients Who Have Planned for Radical Prostatectomy (RP) With High Risk Localized Prostate Cancer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2026
Completion date
October 15, 2030
Enrollment
250 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk localized prostate cancer